Allscripts Healthcare Solutions, Inc., together with its subsidiaries, provides information technology solutions and services to healthcare organizations in the United States, Canada, and internationally. It offers electronic health records (EHR), information connectivity, private cloud hosting, outsourcing, analytics, patient access, and population health management solutions. The company operates in two segments: The Core Clinical and Financial Solutions; and The Data, Analytics and Care Coordination. The Core Clinical and Financial Solutions segment provides software applications for patient engagement, and integrated clinical and financial management solutions, which primarily include EHR-related software; and financial and practice management software solutions, as well as related installation, support and maintenance, outsourcing, private cloud hosting, and revenue cycle management services. The Data, Analytics and Care Coordination segment offers practice reimbursement, and payer and life sciences solutions, which are primarily targeted at physician practices, payers, life sciences companies, and other healthcare stakeholders. Its solutions enable clients to transition, analyze, and coordinate care and enhance the healthcare delivery across the care community. The company serves physicians, hospitals, governments, health systems, health plans, life-sciences companies, retail clinics, retail pharmacies, pharmacy benefit managers, insurance companies, and employer wellness clinics, as well as post-acute organizations, such as home health and hospice agencies. Allscripts Healthcare Solutions, Inc. was founded in 1986 and is headquartered in Chicago, Illinois.
IPO Year:
Exchange: NASDAQ
Website: allscripts.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/19/2024 | $15.00 → $10.00 | Buy → Hold | Deutsche Bank |
| 1/3/2024 | $11.00 | Equal Weight | Barclays |
| 7/6/2023 | Buy → Hold | Argus | |
| 4/12/2023 | $13.00 | Equal-Weight | Stephens |
| 2/1/2023 | $17.00 → $18.50 | Overweight → Neutral | Piper Sandler |
| 12/7/2022 | $26.00 | Hold → Buy | Argus |
| 11/9/2022 | $22.00 → $23.00 | Neutral → Buy | Goldman |
| 11/4/2022 | $17.00 | Overweight | Piper Sandler |
| 9/16/2022 | Sector Weight | KeyBanc Capital Markets | |
| 7/12/2022 | $21.00 | Neutral | Goldman |
SC 13G - Veradigm Inc. (0001124804) (Subject)
SC 13G/A - Veradigm Inc. (0001124804) (Subject)
SC 13G/A - Veradigm Inc. (0001124804) (Subject)
SC 13G/A - Veradigm Inc. (0001124804) (Subject)
SC 13G - Veradigm Inc. (0001124804) (Subject)
SC 13D - Veradigm Inc. (0001124804) (Subject)
SC 13G - Veradigm Inc. (0001124804) (Subject)
SC 13G/A - Veradigm Inc. (0001124804) (Subject)
SC 13G - Veradigm Inc. (0001124804) (Subject)
SC 13G - Veradigm Inc. (0001124804) (Subject)
NEW YORK, Feb. 28, 2024 /PRNewswire/ -- Sprinklr Inc. (NYSE:CXM) will replace Veradigm Inc. (NASD:MDRX) in the S&P SmallCap 600 effective prior to the opening of trading on Monday, March 4. Veradigm will be suspended from the Nasdaq Stock Market on February 29 due to non-compliance with NASDAQ listing rules and is no longer eligible for continued inclusion in the S&P SmallCap 600. Following is a summary of the change that will take place prior to the open of trading on the effective date: Effective Date Index Name Action Company Name Ticker GICS Sector March 4, 2024 S&P SmallCap 600 Addition Sprinklr CXM Information Technology March 4, 2024 S&P SmallCap 600 Deletion Veradigm MDRX Hea
Sales and Operational Veteran Brings Additional Global Business Experience and Healthcare Technology Expertise to Board Omnicell, Inc. (NASDAQ:OMCL) ("Omnicell" or the "Company"), a leader in transforming the pharmacy care delivery model, today announced that the Board of Directors elected Eileen Voynick to the Board, effective January 5, 2024. Ms. Voynick fills the vacancy resulting from Sara J. White, a Class I director who stepped down from the Company's Board of Directors, effective January 5, 2024. In addition, the Company announced that Vance Moore will not stand for reelection to the Company's Board at Omnicell's 2024 annual meeting of stockholders (the "2024 annual meeting") and e
Veradigm Inc. (NASDAQ:MDRX), a leading provider of healthcare data and technology solutions announced today the acquisition of Koha Health, a full-service revenue cycle management (RCM) company. With this acquisition, Veradigm further adds to its depth of offerings and expertise as a leading provider of revenue cycle services in the ambulatory healthcare market. "Today's announcement represents an exciting opportunity for Veradigm to scale our revenue cycle services portfolio by leveraging additional capabilities and subject matter expertise to better serve the needs of the market," said Tom Langan, President, and Chief Commercial Officer at Veradigm. This acquisition brings additional
NEW YORK, Dec. 08, 2023 (GLOBE NEWSWIRE) -- Kaplan Fox & Kilsheimer LLP reminds shareholders that a complaint has been filed on behalf of purchasers of the common stock of Veradigm Inc ("Veradigm" or the "Company") (NASDAQ:MDRX), a healthcare technology company, between February 26, 2021 and June 13, 2023, inclusive (the "Class Period"). Click Here to Join Investigation. If you acquired Veradigm common stock and would like to discuss this case, please click here. You may also contact us by emailing [email protected] or calling (646) 315-9003. If you are a member of the proposed Class, you may move the court no later than January 22, 2024 to serve as a lead plaintiff for the purported
Greg Garrison Named Executive Chairman; Dr. Shih-Yin Ho Appointed Interim CEO; Lee Westerfield Appointed Interim CFO Veradigm Inc. (NASDAQ:MDRX) announced today that the Company's Board of Directors appointed current Chairman, Greg Garrison, as Executive Chairman, and current director, Dr. Shih-Yin ("Yin") Ho, as interim Chief Executive Officer. In addition, Lee Westerfield, who brings more than 25 years of experience as a senior financial executive, most recently serving as Chief Financial Officer at Clearsense, will be serving as Interim Chief Financial Officer. Chief Executive Officer Richard J. Poulton has resigned at the request of the Board from his role as CEO and has stepped dow
New solution to help providers digitally engage with patients, improving both practice efficiency and the patient experience Veradigm, Inc. (NASDAQ:MDRX), a leading provider of healthcare data and technology solutions announced today that it will now offer a new solution to help increase payment rates, accelerate time to payment, and reduce manual reconciliation time for healthcare provider practices. Veradigm Intelligent Payments is a bundle of financial communications and payment solutions and is now available within Veradigm Payerpath via a collaboration with RevSpring, a leading and respected provider of healthcare engagement and payment solutions. Veradigm Intelligent Payments offe
Healthcare IT Industry Expert Will Support the Firm's HCIT Strategy Thomas H. Lee Partners, L.P. ("THL"), a premier private equity firm investing in middle-market growth companies, today announced the appointment of Paul Black as a consultant for the firm's healthcare investment group. Black, who brings more than 25 years of experience leading companies in healthcare information technology ("Healthcare IT"), will support the team's efforts in identifying, sourcing, and growing investment opportunities across the healthcare market. "We are very pleased to welcome Paul to THL as a consultant for the firm's healthcare group," said Shahab Vagefi, Managing Director at THL. "THL has had a longs
WASHINGTON, Dec. 1, 2021 /PRNewswire/ -- Evolent Health, Inc. (NYSE:EVH) ("Evolent"), a health care company that delivers proven clinical and administrative solutions to payers and providers, today announced that Seth R. Frank has joined the company as Vice President, Investor Relations, effective immediately. Reporting to John Johnson, Evolent's Chief Financial Officer, Seth will lead Evolent's investor relations (IR) strategy and oversee its relationships with the investment community. "Seth provides a demonstrated track record of proactive, finance-driven leadership in health care investor relations to Evolent," said Evolent Health Chief Financial Officer John Johnson. "He brings long-ter
4/A - Veradigm Inc. (0001124804) (Issuer)
4 - Veradigm Inc. (0001124804) (Issuer)
NT 10-Q - Veradigm Inc. (0001124804) (Filer)
8-K - Veradigm Inc. (0001124804) (Filer)
8-K - Veradigm Inc. (0001124804) (Filer)
NT 10-Q - Veradigm Inc. (0001124804) (Filer)
8-K - Veradigm Inc. (0001124804) (Filer)
8-K - Veradigm Inc. (0001124804) (Filer)
8-K - Veradigm Inc. (0001124804) (Filer)
8-A12G/A - Veradigm Inc. (0001124804) (Filer)
8-K - Veradigm Inc. (0001124804) (Filer)
NT 10-Q - Veradigm Inc. (0001124804) (Filer)
The AI-powered addition to the Veradigm Network can reduce documentation time, increase operational efficiency, and enhance patient care Veradigm® (OTC:MDRX), a leading provider of healthcare data and technology solutions, announced today the launch of Veradigm Ambient Scribe, an artificial intelligence (AI)-enabled ambient scribe platform designed to ease the documentation burden for healthcare providers. By adding Veradigm Ambient Scribe to the Veradigm Network, Veradigm advances its efforts to provide insightful solutions that drive value for healthcare providers. The solution helps to alleviate the daily administrative burden while enhancing provider-patient interactions. Veradigm A
Leveraging the Veradigm Network to bring real-time insights directly into healthcare provider workflows on behalf of Payers Veradigm® (OTC:MDRX), a leading provider of healthcare data and technology solutions, today announced an enhanced strategic collaboration with Insiteflow, an electronic health record (EHR) decision workflow platform. This effort expands Veradigm Payer Insights (VPI) beyond the Veradigm EHR footprint into additional EHRs technologies. Together, Veradigm and Insiteflow are placing actionable insights on behalf of Payers at the point of care across multiple EHR platforms —including Veradigm EHR and Practice Fusion. VPI is now offered to additional EHR platforms, includi
NLP-enhanced data from over 154 million patient records facilitates innovation in real-world evidence research via the Veradigm Network Veradigm® (OTC:MDRX), a leading provider of healthcare data and technology solutions, announced today the complete integration of advanced natural language processing (NLP) into its electronic health record (EHR) dataset. This integration enhances access to valuable insights from unstructured EHR data and combines it with structured data to create regulatory-grade, real-world data (RWD) that's purpose-built for research. Veradigm Network EHR Data is sourced from over 154 million unique patient records and is one of the most comprehensive ambulatory databa
The Veradigm Network continues to expand, driving value while saving time for healthcare providers and payers Veradigm® (OTC:MDRX), a leading provider of healthcare data and technology solutions, announced today that more than 300,000 healthcare providers throughout the United States are currently using its automated medical chart retrieval solution, Veradigm eChart Courier. This milestone reflects the growing demand for solutions that improve efficiency, reduce administrative burden, and seamlessly connect healthcare providers and payers. "Manual chart chasing is time consuming and resource intensive for health plans and providers," said Tom Langan, Interim CEO, President and Chief Comm
Veradigm received top honors for End-to-End Retrospective Risk Adjustment Solutions Veradigm® (OTC:MDRX), a leading provider of healthcare data and technology solutions, has been named the number one overall vendor by KLAS for broad retrospective vendors, according to the Risk Adjustment 2024 report. This KLAS report examined key factors influencing risk adjustment purchase decisions, noting the growing demand for risk adjustment solutions including both retrospective and prospective capabilities. Veradigm clients reported strong satisfaction with the company's comprehensive suite of solutions, ranking Veradigm as the most recommended vendor. "Veradigm understands that to succeed in toda
For the third consecutive year, Veradigm Payerpath receives #1 overall Black Book ranking for strategic alignment of client goals, integration, and data security Veradigm® (OTC:MDRX), a leading provider of healthcare data and technology solutions, announced today that Black Book™, a healthcare-centric market research and public opinion research and consulting company, rated Veradigm Payerpath the overall number one vendor for end-to-end revenue cycle management (RCM) solutions for physician practice software and services. "At Veradigm, we are dedicated to seamlessly connecting providers with patients and payers. Veradigm Payerpath is integral to that vision," said Tom Langan, Interim Ch
Helping Orthopedists to Measurably Reduce Denials and Improve Practice Revenue Veradigm® (OTC:MDRX), a leading provider of healthcare data and technology solutions, announced today that many orthopedic practice clients utilizing Veradigm Coding Services have observed positive, measurable impacts on key performance indicators for their organizations, with average observed results in the first 12 months including reducing surgical claims payment cycle by up to 5-10%, and increasing Relative Value Units (RVUs, a common metric for office revenue) by up to 3-5%. The increasing complexity of surgical coding and a shortage of qualified coding staff has left practices with a revenue challenge t
Veradigm Network EHR data enables a deeper understanding of the patient journey and disorder progression NEW YORK and CHICAGO, July 24, 2024 /PRNewswire/ -- Holmusk, a leading global mental health real-world evidence company, and Veradigm® (OTC:MDRX), a leading healthcare data and technology solutions provider, today announced that they have reached a new data enrichment milestone in their strategic collaboration. This collaboration, announced last year, draws upon the strengths of each company to drive innovation and generate real-world evidence designed to accelerate mental health research and care. Veradigm also led Holmusk's 2023 Series B funding round as part of this collaboration. To
Payer analytics solutions receive top rankings for Client Satisfaction, Reliability, Best of Breed Technology and Process Improvement Veradigm® (OTC:MDRX), a leading provider of healthcare data and technology solutions, announced today that Black Book Research, a healthcare-centric market research and public opinion research and consulting company, rated Veradigm Payer Analytics the overall number one provider of payer analytics solutions for health plans. Veradigm Payer Analytics achieved #1 in Innovation and Best of Breed technology key performance indicators for payer analytics solutions. Designed to provide actionable insights that help health plans improve overall outcomes and co
For the third consecutive year, the comprehensive set of solutions has been rated the overall #1 provider for small physician practice clearinghouse services Veradigm® (OTC:MDRX), a leading provider of healthcare data and technology solutions, announced today that Black Book Research, a healthcare-centric market research and public opinion research and consulting company, rated Veradigm Payerpath the overall number one provider of claims and clearinghouse platform solutions for small medical practices. Veradigm Payerpath achieved top scores in 11 of 18 clearinghouse-focused key performance indicators for solo and independent practices and small group practices with two to four practitio
Deutsche Bank downgraded Veradigm from Buy to Hold and set a new price target of $10.00 from $15.00 previously
Barclays initiated coverage of Veradigm with a rating of Equal Weight and set a new price target of $11.00
Argus downgraded Veradigm from Buy to Hold
Stephens initiated coverage of Veradigm with a rating of Equal-Weight and set a new price target of $13.00
Piper Sandler downgraded Veradigm from Overweight to Neutral and set a new price target of $18.50 from $17.00 previously
Argus upgraded Allscripts Healthcare from Hold to Buy and set a new price target of $26.00
Goldman upgraded Allscripts Healthcare from Neutral to Buy and set a new price target of $23.00 from $22.00 previously
Piper Sandler resumed coverage of Allscripts Healthcare with a rating of Overweight and set a new price target of $17.00
KeyBanc Capital Markets initiated coverage of Allscripts Healthcare with a rating of Sector Weight
Goldman initiated coverage of Allscripts Healthcare with a rating of Neutral and set a new price target of $21.00
4 - Veradigm Inc. (0001124804) (Issuer)
4 - Veradigm Inc. (0001124804) (Issuer)
4 - Veradigm Inc. (0001124804) (Issuer)
4 - Veradigm Inc. (0001124804) (Issuer)
4 - Veradigm Inc. (0001124804) (Issuer)
4 - Veradigm Inc. (0001124804) (Issuer)
4 - Veradigm Inc. (0001124804) (Issuer)
4 - Veradigm Inc. (0001124804) (Issuer)
4 - Veradigm Inc. (0001124804) (Issuer)
4 - Veradigm Inc. (0001124804) (Issuer)
Veradigm®, Inc. (NASDAQ:MDRX), will report its financial results for the three and twelve months ended December 31, 2022 after the close of the regular stock market hours on Wednesday, March 1, 2023. Veradigm management plans to host a conference call and webcast to discuss the company's earnings at 4:30 p.m. Eastern Time that same day. Fourth-Quarter 2022 Financial Results Call Details To listen to the conference call, participants may log onto the Veradigm Investor Relations website. Participants also may access the conference call by dialing 877-269-7756 or 201-689-7817 and requesting Conference ID # 13735356. A replay of the call will be available for a period of a year on the Veradi
Veradigm Inc. (NASDAQ:MDRX), formerly Allscripts Healthcare Solutions, Inc., announced today that its Board of Directors has approved a new share repurchase program under which Veradigm may purchase up to $250 million of its common stock. The new share repurchase program does not have a termination date and replaces the previous authorization to repurchase $250 million of common stock which was almost fully utilized during 2022. In the fourth quarter of 2022 Veradigm repurchased $57 million of its common stock, bringing its full year total to $234 million. The company also introduced initial financial guidance for Fiscal 2023 as follows: Revenue is expected between $640 million and $660
Third quarter consolidated revenue of $152 million Third quarter consolidated operating profit up over 30% year-over-year Generated $42 million of cash flow from continuing operations in the quarter Allscripts Healthcare Solutions, Inc. (NASDAQ:MDRX) (Allscripts) announced its financial results for the three and nine months ended September 30, 2022. Third quarter 2022 Veradigm revenue was $145 million compared with $137 million in the third quarter of 2021. On a consolidated Allscripts basis third quarter 2022 revenue was $152 million compared with $145 million in the third quarter of 2021. On a GAAP basis, Veradigm income from operations was $28 million in the third quarter of 202
Allscripts Healthcare Solutions, Inc. (NASDAQ:MDRX) will report its financial results for the three months ended September 30, 2022 after the close of stock market hours on Thursday, November 3, 2022. Allscripts management plans to host a conference call and webcast to discuss the company's earnings at 4:30 p.m. Eastern Time that same day. Third-Quarter 2022 Financial Results Call Details The Allscripts earnings announcement will be distributed immediately after the close of regular stock market hours on Thursday, November 3, 2022. The announcement will also be available at Allscripts investor relations website. To listen to the conference call, participants may log onto the Allscripts I
Second quarter bookings of $107 million and $172 million year-to-date, up 10% from the first half of 2021 Generated $42 million of cash flow from continuing operations in the quarter Allscripts Healthcare Solutions, Inc. (NASDAQ:MDRX) (Allscripts) announced its financial results for the three and six months ended June 30, 2022. Second quarter 2022 Veradigm revenue was $145 million compared with $133 million in the second quarter of 2021. On a consolidated Allscripts basis second quarter 2022 revenue was $151 million compared with $141 million in the second quarter of 2021. In the second quarter, Allscripts completed the sale of its Hospital and Large Physician Practices Segment. The
Allscripts Healthcare Solutions, Inc. (NASDAQ:MDRX) will report its financial results for the three months ended June 30, 2022 after the close of stock market hours on Thursday, August 4, 2022. Allscripts management plans to host a conference call and webcast to discuss the company's earnings at 4:30 p.m. Eastern Time that same day. Second-Quarter 2022 Financial Results Call Details The Allscripts earnings announcement will be distributed immediately after the close of regular stock market hours on Thursday, August 4, 2022. The announcement will also be available at Allscripts investor relations website. To listen to the conference call, participants may log onto the Allscripts Investor
First quarter GAAP diluted EPS of $0.17; non-GAAP diluted EPS of $0.13 Closed the sale of Hospital & Large Physician Practices business segment to Constellation Software Generated $35 million of cash flow from continuing operations in the quarter Allscripts Healthcare Solutions, Inc. (NASDAQ:MDRX) (Allscripts) announced its financial results for the three months ended March 31, 2022. First quarter 2022 Veradigm revenue was $136 million compared with $126 million in the first quarter of 2021. On a consolidated Allscripts basis first quarter 2022 revenue was $143 million compared with $134 million in the first quarter of 2021. On a GAAP basis in the first quarter of 2022, Veradigm in
Allscripts Healthcare Solutions, Inc. (NASDAQ:MDRX) will report its financial results for the three months ended March 31, 2022 after the close of stock market hours on Thursday, May 5, 2022. Allscripts management plans to host a conference call and webcast to discuss the company's earnings at 4:30 p.m. Eastern Time that same day. First-Quarter 2022 Financial Results Call Details The Allscripts earnings announcement will be distributed immediately after the close of regular stock market hours on Thursday, May 5, 2022. The announcement will also be available at Allscripts investor relations website. To listen to the conference call, participants may log onto the Allscripts Investor Relati
Allscripts Healthcare Solutions (NASDAQ:MDRX) ("Allscripts") announced today that it has reached an agreement with Constellation Software Inc. (TSX:CSU), through its wholly-owned subsidiary N. Harris Computer Corporation ("Harris"), to sell Harris the net assets of Allscripts Hospitals and Large Physician Practices business segment. The Hospitals and Large Physician Practices business segment includes the Sunrise™, Paragon®, Allscripts TouchWorks®, Allscripts® Opal, STAR™, HealthQuest™ and dbMotion™ solutions. The assets of Allscripts Veradigm business segment are not included in this transaction and will continue to be owned by Allscripts going forward. "The medical industry we faithfully
Fourth quarter GAAP diluted EPS of $0.68; non-GAAP diluted EPS of $0.79 Fourth quarter bookings of $219 million up 21% from the fourth quarter of 2020 Generated $66 million of cash flow from continuing operations in the quarter Allscripts Healthcare Solutions, Inc. (NASDAQ:MDRX) (Allscripts) announced its financial results for the three and twelve months ended December 31, 2021. Bookings(1) were $219 million in the fourth quarter of 2021. This result compares with $181 million in the fourth quarter of 2020. Contract revenue backlog totaled $3.8 billion as of December 31, 2021. Fourth quarter 2021 revenue was $392 million compared with $386 million in the fourth quarter of 2020. On
TD Cowen analyst Charles Rhyee maintains Veradigm (OTC:MDRX) with a Buy and lowers the price target from $26 to $15.
Deutsche Bank analyst George Hill downgrades Veradigm (OTC:MDRX) from Buy to Hold and lowers the price target from $15 to $10.
Veradigm will be suspended from the Nasdaq Stock Market on February 29 due to non-compliance with NASDAQ listing rules and is no longer eligible for continued inclusion in the S&P SmallCap 600.
Gainers Janux Therapeutics (NASDAQ:JANX) stock rose 120.5% to $33.3 during Tuesday's pre-market session. The market value of their outstanding shares is at $1.5 billion. Viking Therapeutics (NASDAQ:VKTX) shares increased by 97.24% to $75.9. The market value of their outstanding shares is at $7.6 billion. TransMedics Gr (NASDAQ:TMDX) stock rose 22.2% to $95.0. The company's market cap stands at $3.1 billion. As per the news, the Q4 earnings report came out yesterday. Codexis (NASDAQ:CDXS) shares rose 21.24% to $3.88. The market value of their outstanding shares is at $270.9 million. Ligand Pharmaceuticals (NASDAQ:LGND) shares moved upwards by 20.93% to $90.0. The company's market cap sta
The transaction will be funded through cash on hand and is not subject to a financing condition. The purchase price to be paid for ScienceIO is $140 million in cash (subject to customary adjustments for cash, indebtedness, working capital and transaction expenses), an aggregate of approximately $44 million of which is deferred and substantially all of which is payable in installments on each of the first three anniversaries of the closing date. The Company has reaffirmed the estimated, unaudited ranges of financial information for fiscal 2023 that it provided on January 10, 2024
The Company also announced that its Board of Directors has unanimously adopted a limited duration stockholder rights plan in anticipation of notification from Nasdaq that it will suspend trading in the stock.
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner. Traders will search for circumstances when the market estimation of an option diverges heavily from its normal worth. High amounts of trading activity could push option prices to exaggerated or underestimated levels. Below are some instances of options activity happening in the Health Care sector: Symbol PUT/CALL Trade Type Sentiment Exp. Date Strike Price Total Trade Price Open Interest Volume MDRX PUT TRADE BULLISH 03/15/24 $7.50 $67.5K 17.8K 2.0K IBRX CALL TRADE BEARISH 01/16
Veradigm Inc. (NASDAQ:MDRX), a leading provider of healthcare data and technology solutions announced today the launch of TRANSFORM VAX, an American College of Cardiology (ACC)-sponsored initiative aimed at improving cardiovascular health through increased influenza vaccination education.Influenza vaccination is associated with a lower risk for adverse cardiovascular events, with an overall 34% lower risk of major adverse cardiovascular events and a 45% lower risk among individuals with recent acute coronary syndrome (ACS).1 As part of this quality improvement initiative, Veradigm is delivering ACC-sponsored vaccination education messaging to a subset of cardiology practices using the Practi
RBC Capital analyst Sean Dodge maintains Veradigm (NASDAQ:MDRX) with a Outperform and lowers the price target from $22 to $11.